Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan PM Mulls Legal Revision on Trial Requirement for Vaccines
April 26, 2021
- Olumiant Snags Japan Approval for COVID-19
April 23, 2021
- MSD’s Recarbrio, Rinvoq’s Psoriasis Use Clears PAFSC Review; June Approval Likely
April 22, 2021
- Major Modifications of CEA Scheme Difficult with Few Examples: Chuikyo
April 22, 2021
- Chuikyo Reps Warn Each Other over 2% Adjustment Rate in Drug Price Revisions
April 22, 2021
- MSD Developing 2-Dose Regimen for 9-Valent HPV Vaccine: Panel
April 22, 2021
- Olumiant Now in Line for Japan Nod for COVID-19 Pneumonia
April 22, 2021
- Vaccine Industry Group Calls for Govt’s Control Functions for Infectious Diseases
April 21, 2021
- Japan Officially Announces CEA-Based Prices for Kymriah/Trelegy, Effective July 1
April 21, 2021
- FPMAJ Chief Calls for Uninterrupted Govt Support for Japan-Made Vaccines Even in Ordinary Times
April 20, 2021
- Over 50% of Itraconazole ADR Reporting Comes from Pharmacists in October-December: PMDA
April 20, 2021
- Automatic Listing for Approved Drugs Erodes Financial Predictability: MOF
April 19, 2021
- MHLW to Revoke Approval of 12 Kobayashi Kako Products as Documents Fabricated
April 19, 2021
- Industry Veteran Prods Appropriate Evaluation for Innovation: LDP Confab
April 16, 2021
- Chuikyo Receives Report on Fertility Treatment Survey, Awaits Guidelines to Discuss Coverage
April 16, 2021
- 2 New Payer Members Make Chuikyo Debut
April 15, 2021
- Ultomiris Now Braced for Price Cut as Chuikyo OKs CEA Results
April 15, 2021
- LDP Project Team to Compile Proposal on Japan-Made Vaccine Development
April 15, 2021
- Bayer’s Heart Failure Med Vericiguat Up for 2nd PAFSC Review
April 15, 2021
- MHLW Presents Discussion Timeline for FY2022 Reform
April 15, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…